COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01101139
Recruitment Status : Completed
First Posted : April 9, 2010
Last Update Posted : December 17, 2012
Information provided by (Responsible Party):
Technische Universität München

Brief Summary:
This study is designed to investigate, whether Sugammadex improves muscle function after standard neuromuscular recovery (TOF 0.9) from relaxation with rocuronium.

Condition or disease Intervention/treatment Phase
Neuromuscular Blockade Drug: Sugammadex Drug: Placebo Phase 4

Detailed Description:

Muscle relaxants are an integral part of today's anesthesia. They improve intubating conditions and reduce doses of other substances needed for general anesthesia. For ensuring patient safety, neuromuscular function is monitored during general anesthesia. The latter one is only terminated, when neuromuscular monitoring shows an objective normal value. Despite this accurate surveillance, a lot of patients complain about subjectively uncomfortable muscle weakness in the recovery room. A possible explanation for this ostensive contradiction can be the variable "margin of safety" of neuromuscluar transmission in different muscle groups. Waud et al describe this phenomenon, as the fact, that neuromuscular transmission is only clinically detectable, when a certain number of post-synaptic receptors is not blocked. The necessary fraction of free receptors differs a lot between the muscle groups (15-50%). As neuromuscular monitoring only measures one muscle group exemplarily, and a clinically non-detectable number of post-synaptic receptors can be blocked shortly after anesthesia, the subjective muscle weakness of patients could need treatment.

Sugammadex can encapsulate steroid-typ muscle relaxants within 2 to 5 minutes. After applying a sufficiently high dose, also those receptors will be free that elude neuromuscular monitoring. This constellation brings up the interesting problem to quantify the possible effect on patients' subjective muscle weakness.

This study is designed to investigate, if the application of sugammadex improves muscle function and consequently well-being of patients, that have been extubated according to clinical standard.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Small Dose of Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery (TOF 0.9)
Study Start Date : April 2010
Actual Primary Completion Date : May 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Experimental
Single injection of Sugammadex 0.25 mg/kg
Drug: Sugammadex
Sugammadex (single intravenous injection 0.25 mg/kg)

Placebo Comparator: Placebo comparator
Single injection of Saline 0.9%
Drug: Placebo
Placebo: single intravenous injection Saline 0.9%

Primary Outcome Measures :
  1. Muscle function
    Muscle function following the investigational drug

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ASA physical stauts II - III
  • Age: 18 - 65 years
  • Patients scheduled for general anesthesia with intubation using rocuronium
  • Patients have given informed consent to the study
  • Patients receiving the investigational drug within 15 minutes after neuromuscular recovery to a TOF 0.9
  • Sufficient knowledge of the German language

Exclusion Criteria:

  • known or suspected neuromuscular disease
  • significant hepatic or renal dysfunction
  • known or suspected history or family history of disposition to malignant hyperthermia
  • known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other drugs used for general anesthesia
  • Use o drugs that interfere with sugammadex
  • Patients included in another trial within the last 30 days
  • Patients with legal guidant
  • Patients with contradiction towards the use of Sugammadex
  • Pregnant women
  • Breast-feeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01101139

Layout table for location information
Klinik für Anaesthesiologie Klinikum München rechts der Isar
Munic, Bavaria, Germany, 81675
Sponsors and Collaborators
Technische Universität München
Layout table for investigator information
Principal Investigator: Manfred Blobner, M.D. Klinik für Anaesthesiologie Klinikum München rechts der Isar
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Technische Universität München Identifier: NCT01101139    
Other Study ID Numbers: SIMAR
First Posted: April 9, 2010    Key Record Dates
Last Update Posted: December 17, 2012
Last Verified: December 2012